Connect with us

Startup Stories

How Boltzmann Is Using GenAI To Speed Up Drug Discovery

Published

on


SUMMARY

Founded in 2019, the Bengaluru-based startup wants to make a breakthrough in the drug discovery space with its AI models

Boltzmann’s AI drug discovery tech stack comprises four more platforms — ReBolt, BoltPro, BoltBio, and ClinBolt

The startup is looking to collaborate with top international players in the larger drug discovery space, which is dominated by the likes of Pfizer, GSK, and Eli Lilly

At a time when GenAI is demonstrating its might in serving every industry possible, healthcare is one of the domains that, too, stands poised to harness its true potential across a range of applications, including lab assistance, clinical diagnosis, health monitoring, and drug discovery.

Though the application of GenAI today is largely restricted to text, video, and audio generation, there is a whole treasure trove of use cases being unlocked for healthcare professionals in pharma companies, clinics and hospitals. 

It is pertinent to note that despite being one of the top global players in the pharmaceutical space, the Indian drug discovery ecosystem has faced multiple hurdles, including high failure rates and high costs.

However, with GenAI making exponential strides, the Indian pharmaceutical space is expected to witness a major boost, as the tech has the potential to substantially reduce cost and failure rates in the drug development process.

Interestingly, entrepreneur and AI researcher Sarath Kolli was able to connect these dots right before the buzz around GenAI and started leveraging the tech to enable drug discovery and improve the success rate of clinical trials.

This led to the incorporation of Boltzmann, an Indian GenAI startup working in the fields of AI and Drug Discovery, in 2019. Bengaluru-based startup Boltzmann began building AI models, with an aim to make a breakthrough in AI drug discovery.

Speaking with Inc42, Boltzmann’s founder and CEO Kolli said, “In India, if we look at the drug discovery landscape, we will observe that big companies like Redis Labs, Piramal, and many others closed their drug discovery units. Overall, the drug discovery landscape in the country has shrunk in the last decade. So, we started with the vision to enable this industry with better technologies to reduce the risks and improve success rates in clinical trials.”

Boltzmann’s AI Stack For Drug Manufacturers 

Initially started as a community, which ran for almost a year for conducting experiments and research related to problems in drug discovery, Boltzmann started developing its first product BoltChem in 2020. 

The platform (BoltChem) enables the designing of novel drugs using open-source models. The startup claims that the BoltChem platform makes predicting properties and exploring the chemical space of a molecule significantly less time-consuming. The platform has been developed to help drug developers come up with novel small molecules within a few months as against several years taken in traditional methods.

“We have also fine-tuned these open-source models and built our own models that are incorporated into our platforms. Users have the option to automatically fine-tune them according to their requirements,” Kolli said.

The startup has four more platforms — ReBolt, BoltPro, BoltBio, and ClinBolt. 

Using GenAI and by extracting data from BoltChem, ReBolt generates a synthetic pathway for making a molecule in the chemistry labs. The ReBolt platform has been developed with a vision to optimise R&D processes for Indian drug manufacturers.

Its BoltBio platform helps to identify the real reason behind a particular disease, hence making the treatment of any rare or common diseases easier. The product’s beta launch is expected this year.

Similarly, ClinBolt uses patient data to design clinical trials and predict the outcomes of a certain treatment. Both BoltBio and ClinBolt are the latest products in Boltzmann’s quiver. 

Meanwhile, BoltPro is an AI-powered protein engineering platform, which helps in designing vaccines and antibodies.

Boltzmann factsheet

Boltzmann has built models, along with utilising the open-source large language models (LLMs) and other GenAI models available in the market today. For instance, it has leveraged protein language models such as ESM, developed by Meta and Google DeepMind’s AlphaFold2 to build the platforms.

While the startup did not reveal the names of its clients, it claimed to be currently working with certain Indian drug research institutes. The startup is also in talks with the top 10 global pharma companies for the deployment of its platforms.

Boltzmann has raised about $200K from a few angel investors since its inception.

How Does Boltzmann Make Money?

Currently, the startup has three means of revenue generation, including its SaaS (available in monthly, quarterly, and yearly subscriptions) and a fee-for-service model. Besides, it also partners with other biotech and pharma companies in drug development for particular diseases.

Interestingly, Boltzmann has opted not to limit the use of its GenAI models solely for third-party deployment. Instead, the startup ventured into in-house drug discovery last year utilising its platforms.

Kolli said that while its GenAI application vertical has a quick commercial prospect, given the increasing use of technology in healthcare, its in-house drug discovery vertical will take a few years before it starts generating revenue. However, going forward, the second vertical has the largest prospect in terms of revenue generation for Boltzmann.

The startup’s current ARR stands at around $200K, which is expected to gain increased momentum as Boltzmann has set its eyes on global expansion.

What Lies Ahead?

Currently, Boltzmann is focused on cracking deals with a global pharma giant for the deployment of its product. Besides, the startup is also looking to raise $3 Mn in a fresh funding round from VCs.

The company is also exploring a few mergers and acquisitions (M&A) opportunities. It has already onboarded the leader of Bengaluru-based Serocode Biolabs and Eviogen, Dr Paritosh Prashar as its cofounder.

In 2024, the startup is aiming to launch a general version of its BoltPro and ClinBolt platforms.

The startup is looking to collaborate with top international players in the larger drug discovery space, which is dominated by the likes of Pfizer, GSK, and Eli Lilly. In the AI drug discovery space, Boltzmann currently competes with global companies including Insilico Medicine, Recursion AI, and Exscientia.

As per a report, the Indian market for AI in drug discovery is projected to become an INR 2.57 Lakh Cr market opportunity by 2028. For now, it will be interesting to see how Boltzmann succeeds in creating a niche in the Indian drug discovery market by leveraging the power of GenAI.

[Edited by Shishir Parasher]





Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Startup Stories

Byju’s partially pays March salaries, pending February payouts.

Published

on

By

Byju’s, a prominent player in the edtech industry, has encountered financial challenges resulting in delayed salary payments for its employees. As of April 20, the company has only disbursed a portion of March salaries, attributing the delay to a severe cash crunch. Despite earlier assurances from the company’s management that salaries for March would be paid by April 18, many mid-senior employees have reported receiving only 50% of their March salaries. Additionally, February salaries remain unpaid for a significant number of employees, further exacerbating the situation.

Founder and CEO, Byju Raveendran, has resorted to raising personal debt against his stakes in the company to facilitate salary payments. This underscores the severity of the financial challenges facing Byju’s and highlights the lengths to which Raveendran is willing to go to address the issue.

Employee testimonies reveal the extent of the salary delays, with one employee stating that they received only 50% of their March salary on April 20, with 80% of their February salary still pending. Another concerning aspect is the reported disparity between junior and senior employees, with junior staff receiving full salary payments while top management has gone without salaries for the past two months.

Byju’s has acknowledged the delay in salary payments but has not provided a detailed explanation for the situation. A company spokesperson declined to comment on queries from ET regarding the matter. In an email sent to employees on April 8, the management team expressed regret over the delay and attributed it to the inability to secure approval to access funds from a rights issue. The delay has been further compounded by actions from foreign investors, hindering the company’s access to necessary funds.

This revelation follows a previous report by ET on April 1, which highlighted Byju’s decision to delay salary payments due to constraints imposed by warring investors, limiting the company’s access to funds through a rights issue. The ongoing dispute with investors, including Dutch investor Prosus, has added to Byju’s financial woes and has led to further delays in resolving the issue.

In a separate development, Byju’s India chief executive, Arjun Mohan, announced his departure from the company in mid-April, just six months after assuming the role. This unexpected move prompted founder Byju Raveendran to take on the responsibility of overseeing day-to-day operations of the company’s India business, housed under Think & Learn, marking a significant shift in leadership.

Amidst these challenges, Byju’s is embroiled in a legal battle with a group of investors led by Prosus, who are seeking to block a rights issue and the removal of Byju Raveendran as CEO. The company has also initiated arbitration proceedings to address the dispute and find a resolution.

The rights issue undertaken by Byju’s is significant, as it is being offered at a staggering 99% discount to the company’s peak valuation of $22 billion. This steep discount has implications for investors who choose not to participate in the funding, potentially resulting in a significant dilution of their shareholding post-completion of the rights issue.

The unfolding events at Byju’s underscore the challenges facing the edtech giant as it navigates financial constraints, leadership transitions, and legal disputes. The company’s ability to address these issues effectively will determine its future trajectory and its ability to maintain its position in the competitive edtech landscape.

Continue Reading

Startup Stories

Revolut India receives provisional approval for PPI license from RBI

Published

on

By

Revolut India, a neobank backed by Tiger Global and Softbank, has secured an in-principle approval from the Reserve Bank of India (RBI) for issuing Prepaid Payment Instruments (PPI), encompassing prepaid cards and wallets. CEO Paroma Chatterjee shared this development in a LinkedIn post on Friday. This approval complements Revolut India’s existing licenses from the RBI, which allow it to function as a Category-II Authorised Money Exchange Dealer (AD II), enabling the issuance of multi-currency forex cards and cross-border remittance services.

Chatterjee emphasized the significance of this milestone, highlighting the opportunity it presents to provide Indian consumers with both international and domestic payment solutions on a unified platform. Revolut, Europe’s largest neobank, entered the Indian market in 2021 with aspirations to disrupt the domestic payments sector. The RBI’s approval is expected to bolster Revolut’s position as a key player in this domain.

Prepaid Payment Instruments (PPIs) are payment tools that utilize stored monetary value, including digital wallets, smart cards, or vouchers, for transactions. RBI Governor Shaktikanta Das proposed on April 5, 2024, to allow PPIs to be linked through third-party UPI applications, enabling PPI holders to conduct UPI payments akin to bank account holders.

Chatterjee underscored Revolut’s commitment to full compliance with regulatory requirements, particularly in India, where the neobank has undertaken significant efforts to localize its global tech-stack to adhere to local regulations.

In an interview with ET BFSI, Chatterjee disclosed Revolut’s plans to introduce a comprehensive suite of digital-first money management services for all Indian customers. These services will enable users to manage their finances, including payments and remittances, both domestically and internationally.

The app, currently in use by employees, will be officially launched once the internal testing phase is completed, according to Chatterjee. She also revealed that there are over 175,000 prospective customers on Revolut India’s waitlist, indicating strong interest in the product.

Continue Reading

Startup Stories

Postman buys Orbit to extend developer community reach.

Published

on

By

Postman, renowned as an API management platform tailored for enterprises, has recently made headlines with its acquisition of Orbit, a pivotal tool in the arsenal of developer companies for nurturing communities across a spectrum of platforms, including Discord, Slack, and GitHub. Although the specifics of the financial transaction remain undisclosed, Postman took to its blog to underline Orbit’s indispensable role in supporting major developer companies in fostering community management and fostering growth over the course of the past four years.

Within the ecosystem of Postman, the integration of Orbit is poised to be transformative, with the Orbit team set to assume a pivotal role in seamlessly embedding community-centric features into the fabric of the Postman Public API Network. This strategic move is aimed at catalyzing dynamic collaboration between content creators and end-users within the network. Postman, boasting a staggering valuation of $5.6 billion, stands as a stalwart in the realm of API collaboration platforms, serving a user base exceeding 30 million developers and 500,000 organizations.

Under the stewardship of Noah Schwartz, a recent addition to the Postman team hailing from Amazon Web Services, the Orbit team is primed to spearhead initiatives aimed at empowering API distributors to broaden the horizons of their communities, optimize API utilization, and solicit direct feedback from users entrenched within the network.

This integration is anticipated to embolden developers to unearth APIs tailored to their unique requirements and foster meaningful engagements with peers to extract maximum value from each API. However, as part of the transitionary phase, Orbit has outlined plans to gradually phase out its existing product and platform over the span of the next 90 days. Commencing July 11, all functionalities will be deactivated, with no provision for the creation of new users or workspaces.

Postman’s strategic maneuver comes on the heels of its triumphant fundraising endeavor in 2021, securing a whopping $225 million in funding. The fundraising round, spearheaded by Insight Partners, witnessed active participation from prominent entities such as Coatue, Bond Capital (helmed by Mary Meeker), and Battery Ventures.

Continue Reading

Trending

Copyright © 2017 Zox News Theme. Theme by MVP Themes, powered by WordPress.